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1Although randomized controlled trials represent the “gold standard” for assessment of comparative efficacy, there 
are frequent concerns about the generalizability of the results 
to the broader population of patients seen in clinical practice.1 
In the Prospective Comparison of ARNI With an Angiotensin-
Converting Enzyme Inhibitor to Determine Impact on Global 
Mortality and Morbidity in Heart Failure (PARADIGM-HF) 
trial, treatment with sacubitril/valsartan (LCZ696) led to sta-
tistically significant and clinically important reductions in 
cardiovascular death, all-cause death, and heart failure (HF) 
hospitalization, compared with enalapril.2 However, the random-
ized patients in PARADIGM-HF represent a subset of a larger 
cohort eligible for the initial single-blind, sequential run-in 
period ensuring short-term tolerability of target doses of both 
enalapril and LCZ696 before randomization. In an effort to bet-
ter understand the applicability of the PARADIGM-HF results to 
a less-selected population, we analyzed the patient characteris-
tics associated with run-in noncompletion before randomization 
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Background—The 8442 patients randomized in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor 
With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart 
Failure (PARADIGM-HF) trial, in which sacubitril/valsartan (LCZ696) reduced both death and HF hospitalization more 
than enalapril, were a subset of 10 521 patients entering sequential, single-blind run-in periods (enalapril 10 mg twice 
daily for 2 weeks followed by LCZ696 200 mg twice daily for 4 to 6 weeks) to ensure short-term tolerability of the 2 
study medications. We identified the predictors of run-in noncompletion and estimated the implications of noncompletion 
for the overall study result.
Methods and Results—Patient factors associated with run-in noncompletion were defined in multivariable logistic regression 
models. The effectiveness of LCZ696 in a broader cohort approximating the full run-in population was estimated by weighting 
randomized patients according to the inverse probability of run-in completion; 2079 (19.8%) subjects discontinued the study 
during the run-in period, including 1102 (10.5%) during the enalapril phase and 977 (9.3%) during the LCZ696 phase. In 
multivariable models, lower systolic blood pressure, lower estimated glomerular filtration rate, higher N-terminal pro–B-type 
natriuretic peptide, and ischemic cause of heart failure were associated with higher risk for run-in noncompletion. Repeat 
analysis of the effect of randomized treatment giving greater weight to randomized patients resembling those who did not 
complete the run-in did not alter the hazard ratio favoring LCZ696 over enalapril for the primary end point of cardiovascular 
death or heart failure hospitalization, or the additional key end points of cardiovascular death and all-cause mortality.
Conclusions—Patients with lower blood pressure, lower glomerular filtration rate, and more severe heart failure were at 
higher risk for noncompletion during the run-in period of PARADIGM-HF. Weighted analysis of key study outcomes 
accounting for the effect of run-in noncompletion did not alter the benefit of LCZ696 over enalapril.
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and the implications of these prerandomization exclusions for 
the observed study result.
Methods
PARADIGM-HF Trial
The detailed study design, methods, and principal results of the 
PARADIGM-HF study have been previously reported.2,3 Briefly, the 
study was a randomized, double-blind, prospective comparison of the 
angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in 
subjects with chronic HF and reduced left ventricular ejection frac-
tion. Key eligibility criteria at the time of screening included: age of 
at least 18 years, New York Heart Association class II–IV symptoms, 
left ventricular ejection fraction ≤40%, elevated plasma B-type na-
triuretic peptide (BNP) ≥150 pg/mL (or N-terminal pro-BNP ≥600 
pg/mL) at the time of screening or BNP ≥100 pg/mL (or N-terminal 
pro-BNP ≥400 pg/mL) and a hospitalization for HF in the 12 months 
before enrollment, treatment with a stable dose of angiotensin-con-
verting enzyme inhibitor or angiotensin-receptor blocker equivalent 
to at least 10 mg enalapril daily for at least 4 weeks, and treatment 
with a stable dose of β-blocker for at least 4 weeks unless contrain-
dicated or not tolerated. Key exclusion criteria at screening included 
symptomatic hypotension, systolic blood pressure (BP) <100 mm Hg, 
estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m2 
of body surface area, serum potassium >5.2 mmol/L, and history of 
angioedema or other serious side effects during treatment with an 
angiotensin-converting enzyme inhibitor or angiotensin-receptor 
blocker.
All patients deemed eligible at the screening visit entered se-
quential, single-blind run-in periods to assess tolerability of enalapril 
and LCZ696 at target doses. During the first run-in period, patients 
received enalapril 10 mg twice daily for 2 weeks. Those tolerating 
enalapril (defined as maintenance of serum potassium ≤5.4 mmol/L, 
eGFR ≥30 mL/min per 1.73 m2 of body surface area with decline 
of ≤35% from screening value, and systolic BP ≥95 mm Hg with-
out symptomatic hypotension, postural symptoms, or other adverse 
events precluding continued participation) were permitted to enter 
the second run-in period, during which they received LCZ696 at an 
initial dose of 100 mg twice daily for 1 to 2 weeks, titrated to 200 mg 
twice daily for an additional 2 to 4 weeks. Those tolerating LCZ696 
(defined as for the enalapril run-in) were then randomly allocated 
in 1:1 fashion to double-blind treatment with either enalapril 10 mg 
twice daily or LCZ696 200 mg twice daily. The study was approved 
by the institutional review board or ethics committee at each site, 
and all enrolled subjects provided written informed consent before 
participation.
Statistical Methods
We tabulated the reasons for study discontinuation during each phase 
of the run-in period before randomization. Baseline characteristics 
were defined at screening to compare those who did not complete 
the run-in period with those who were ultimately randomized, with 
continuous variables assessed using Student t test and categorical 
variables assessed using standard χ2 tests. Multivariable predictors 
of prerandomization dropout for any reason were identified via a 
logistic regression model using a stepwise forward selection algo-
rithm derived from available patient characteristics including region 
of enrollment (see Methods section in the Data Supplement for full 
list of candidate variables). To evaluate the stability of these predic-
tors, sensitivity analyses were performed restricting the models to 
those in whom the reason for noncompletion was either related to an 
adverse event or abnormal laboratory value or was unknown. These 
logistic regression models were used to estimate the probability of 
being randomized for each run-in patient. To account for the impact 
of prerandomization noncompletion on the efficacy of LCZ696 rela-
tive to enalapril during the double-blind treatment period, we reana-
lyzed the treatment effect for the primary composite end point (death 
from cardiovascular causes or first hospitalization for HF) using Cox 
proportional hazards models, using inverse probability weighting, 
based on the previously described probability estimates. The effect 
of these inverse probability weighting models is to add additional 
weight to randomized patients most closely resembling the profile 
of patients excluded during the run-in, to minimize the effect of hav-
ing excluded such patients from the trial. Sensitivity analyses were 
conducted using alternative weights reflecting dropouts for adverse 
events, abnormal laboratories, or unknown reasons only (excluding 
dropouts for death, protocol violations, or administrative reasons) 
and using overweighting to simulate varied assumptions about the 
proportion of patients discontinuing study before randomization. As 
additional analysis, we performed simulations in which 1040 pa-
tients were added to each treatment arm to represent the patients who 
failed to complete the run-in. For these simulated patients, we as-
sumed no impact of LCZ696 and generated primary end point event 
times and censoring times from exponential and uniform distribu-
tions, respectively, intended to mimic those from the actual trial data. 
We then increased the imputed event rates for these patients to reflect 
the frailty of the run-in failures. For each setting, we simulated data 
for 2080 run-in HF patients, calculated the resulting treatment effect 
hazard ratio (HR) and confidence interval (CI) for each augmented 
data set, repeated this process 200 times, and then reported the aver-
age HR and CI across these 200 replications. P values <0.05 were 
considered statistically significant. All analyses were conducted in 
STATA version 13.0 (College Station, TX).
Results
Of 10 521 initially eligible subjects, 8442 (80.2%) were even-
tually randomized during the double-blind treatment period. 
Of the 2079 (19.8%) subjects who discontinued the study 
before randomization, 1102 (10.5%) failed to complete the 
enalapril run-in phase and 977 (9.3%) did not complete the 
LCZ696 phase. The reasons for noncompletion are detailed 
in Table 1. Roughly two thirds of subjects failed to complete 
the run-in because of adverse events or abnormal test results. 
Among adverse events prompting study drug discontinua-
tion, the most common were hypotension, hyperkalemia, and 
worsening renal function. Angioedema was rare, occurring in 
25 subjects (0.2%) entering the run-in. A larger proportion of 
noncompletion for cough and hyperkalemia occurred during 
the initial (enalapril) run-in phase, whereas rates of discon-
tinuation for hypotension and worsening renal function were 
higher during the second (LCZ696) phase of the run-in period.
Patient characteristics assessed at the screening visit for 
those who did not complete the run-in period versus those 
who were randomized are displayed in Table 2 and are fur-
ther categorized by phase of run-in discontinuation in Table I 
in the Data Supplement. Subjects who discontinued the study 
before randomization were more commonly enrolled outside 
of Central/Eastern Europe and more likely to be older, non-
white, and female with more severe HF symptoms, an isch-
emic pathogenesis, lower systolic BP, lower eGFR, higher 
natriuretic peptide levels, and higher rate of utilization of 
implantable cardioverter-defibrillator/cardiac resynchroniza-
tion therapy. After multivariable adjustment, the predictors 
of dropout during the run-in period included lower systolic 
BP, higher N-terminal pro-BNP, eGFR <60 mL/min per 1.73 
m2, ischemic cause of HF, and region of enrollment (Table 3). 
Other than the cause of HF, which was associated with drop-
out only during the enalapril portion of the run-in, these pre-
dictors were largely consistent across the 2 run-in phases 
(Table II in the Data Supplement). Sensitivity analyses that 
focused on those who did not complete the run-in period spe-
cifically because of adverse events, laboratory abnormalities, 
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or unknown reasons did not substantially alter the key pre-
dictors. Those who discontinued either drug for hypotension 
during the run-in period tended to have lower mean systolic 
BP at screening than those who failed to complete the run-
in for other reasons (117±14 mm Hg versus 126±17 mm Hg, 
P<0.001).
To determine whether the primary results would have been 
different had we included more patients like those who did 
not complete the run-in period, we used inverse probability 
weighting, in which patients in the randomized set with base-
line characteristics were most similar to those who did not 
complete the run-in period were weighted more heavily. This 
approach did not alter the HR favoring LCZ696 over enalapril 
with regard to the primary outcome of cardiovascular death or 
HF hospitalization (HR, 0.80; 95% CI, 0.73–0.87; P<0.001) 
or with regard to the key additional end points of cardiovas-
cular death (HR, 0.80; 95% CI, 0.71–0.89; P<0.001) and 
all-cause mortality (HR, 0.84; 95% CI, 0.76–0.92; P<0.001; 
Figure). Sensitivity analyses using overweighting to simulate 
extreme scenarios in which 50%, 80%, and 100% of the ran-
domized population were similar to the patients who failed to 
complete the run-in period did not alter these results (Table 
III in the Data Supplement), nor did assigning drug-specific 
weights based on phase-specific noncompletion data from 
the run-in period. Estimates of treatment benefit in the full-
screened population when assuming a neutral effect of ran-
domized treatment for those who failed to complete the run-in 
period were largely consistent for the primary end point (HR, 
0.84; 95% CI, 0.78–0.91; P<0.001) and were not materially 
influenced by variation in the assumed event rate for run-in 
failures (Table IV in the Data Supplement).
Table 1. Reasons for Dropout During Run-In Period
Reason
Discontinued Study 
During Enalapril Run-In 
Period (n=1102)
Discontinued Study 
During LCZ696 Run-
In Period (n=977)
Adverse event* 591 (53.7%) 547 (56.1%)
  Cough 49/591 (8.3%) 15/547 (2.7%)
  Hyperkalemia 174/591 (29.4%) 123/547 (22.5%)
  Hypotension 146/591 (24.7%) 163/547 (29.8%)
  Renal dysfunction 181/591 (30.6%) 173/547 (31.6%)
  Angioedema 15/591 (2.5%) 10/547 (1.8%)
  Other 102/591 (17.3%) 131/547 (23.9%)
Abnormal laboratory test 55 (5.0%) 49 (5.0%)
Other abnormal test result 11 (1.0%) 9 (0.9%)
Withdrew consent 171 (15.5%) 100 (10.3%)
Protocol violation or 
deviation
79 (7.2%) 91 (9.3%)
Lost to follow-up 39 (3.5%) 26 (2.7%)
Administrative problems 20 (1.8%) 29 (3.0%)
Death 49 (4.5%) 47 (4.8%)
Other specified cause 5 (0.5%) 12 (1.2%)
Unknown 81 (7.4%) 65 (6.7%)
*Patients may have reported >1 adverse event.
Table 2. Baseline Characteristics at Screening (Before Run-
In), According to Dropout During Run-In Period
Characteristics at 
Screening
Discontinued 
Study During  
Run-In Period 
(n=2079)
Randomized 
(n=8442) P Value
Age, y 64.8±11.8 63.8±11.4 <0.001
Region
  USA/Canada 218 (10.5%) 602 (7.1%)
<0.001
  Latin America 381 (18.3%) 1458 (17.3%)
  Western Europe 
and Other
593 (28.5%) 2057 (24.4%)
  Central/Eastern 
Europe
512 (24.6%) 2837 (33.6%)
  Asia-Pacific 375 (18.0%) 1488 (17.6%)
Race or Ethnic Group
  White 1314 (63.2%) 5579 (66.1%)
0.05
  Black 131 (6.3%) 428 (5.1%)
  Asian 380 (18.3%) 1510 (17.9%)
  Other 254 (12.2%) 925 (10.9%)
Female sex 499 (24.0%) 1847 (21.9%) 0.04
Height, cm 167.7±10.1 168.7±9.6 <0.001
Weight, kg 77.9±19.4 80.4±19.3 <0.001
Systolic BP, mm Hg 124.9±17.0 128.4±16.7 <0.001
BMI, kg/m2 27.5±5.7 28.1±5.66 <0.001
eGFR, mL/min per 
1.73 m2
63.9±22.6 68.1±19.3 <0.001
Serum creatinine, 
mg/dL
1.20±0.35 1.11±0.28 <0.001
NYHA class <0.001
  I/II 1274 (61.5%) 5481 (65.0%) <0.001
  III/IV 798 (38.5%) 2952 (35.0%) <0.001
Median NT-proBNP, 
pg/mL, [IQR]
2071 [1011, 4669] 1612 [887, 3226] <0.001
Ejection fraction, % 28.5±6.5 29.5±6.2 <0.001
Ischemic 
pathogenesis
1325 (63.7%) 5058 (59.9%) 0.001
ICD 417 (20.1%) 1246 (14.8%) <0.001
CRT 199 (9.6%) 575 (6.8%) <0.001
Diabetes mellitus 753 (36.2%) 2916 (34.5%) 0.15
Hypertension 1371 (65.9%) 5970 (70.7%) <0.001
Coronary heart 
disease
1149 (55.3%) 4607 (54.6%) 0.57
Atrial fibrillation 697 (33.5%) 3111 (36.9%) 0.005
Pretrial use of ACE-I 1578 (75.9%) 6560 (77.7%) 0.08
Pretrial use of ARB 499 (24.0%) 1907 (22.6%) 0.17
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-
receptor blocker; BMI, body mass index; BP, blood pressure; CRT, cardiac 
resynchronization therapy eGFR, estimated glomerular filtration rate; ICD, 
implantable cardioverter-defibrillator IQR, interquartile range; NT-proBNP, 
N-terminal pro–B-type natriuretic peptide; and NYHA, New York Heart Association.
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Discussion
Approximately 20% of patients did not complete the run-
in period of PARADIGM-HF and were not randomized, 
therefore, not included in the primary analyses. Roughly 
half of the early discontinuations occurred during the 
2-week enalapril run-in period, with the balance occurring 
during the 6-week LCZ696 run-in period. The reasons for 
run-in noncompletion were predominantly related to drug-
related adverse events (most commonly cough, hyperkale-
mia, hypotension, or renal dysfunction) or withdrawal of 
consent, with a minority related to death, protocol devia-
tions, or administrative reasons. Noncompletion occurred 
at similar rates and for similar reasons during the enalapril 
and LCZ696 phases of the run-in period, though by design, 
patients intolerant of enalapril did not enter the LCZ696 
run-in period. Patients with lower BP, higher natriuretic 
peptide levels, ischemic heart disease, and eGFR <60 mL/
min per 1.73 m2 were at higher risk for discontinuation 
of either enalapril or LCZ696 during the run-in period of 
PARADIGM-HF. Reanalysis of the randomized data assign-
ing increased weight to patients with baseline characteris-
tics most similar to those who failed to complete the run-in 
period did not influence the apparent benefit of LCZ696 
over enalapril seen during the trial.
A run-in period was included in the design of 
PARADIGM-HF to achieve 2 primary goals. The first was to 
ensure comparison of LCZ696 to the established standard of 
care in HF with reduced ejection fraction by selecting patients 
who could tolerate enalapril at the target dose (10 mg twice 
daily) that had been demonstrated to reduce mortality in the 
Studies of Left Ventricular Dysfunction (SOLVD)-Treatment 
trial. The second, in the absence of any substantial Phase II 
clinical trial, was to provide open-label, short-term data on the 
tolerability of LCZ696 at the target dose of 200 mg twice daily.3
The inclusion of a run-in period has potential implica-
tions for the clinical applicability of the overall study results 
of a clinical trial because the randomized population reflects 
a subgroup of initially eligible patients that cannot easily be 
defined a priori; selecting similar patients in clinical practice 
requires observation of response to the drug over time. In this 
article, we address this concern by highlighting the patient 
characteristics differentiating the run-in eligible population 
from those ultimately randomized. Because both enalapril and 
LCZ696 are drugs that inhibit the renin–angiotensin system 
and cause vasodilation, it is not surprising that subjects with 
lower systolic BP and worse renal function were at higher risk 
for noncompletion. Similarly, the association of study discon-
tinuation with higher natriuretic peptide levels and ischemic 
heart disease may reflect the anticipated intolerance of renin–
angiotensin system antagonists in patients with more advanced 
HF.4 Importantly, however, none of the patient characteristics 
examined was a guarantee of run-in noncompletion, and many 
patients who were at high-risk by these criteria were success-
fully randomized in PARADIGM-HF. Although the sequential 
nature of the run-in period makes it challenging to directly 
compare the tolerability of enalapril and LCZ696, rates of 
study drug discontinuation for reasons other than death dur-
ing median 27 months follow-up in the randomized treatment 
period were similar between the 2 arms (17.8% and 19.8% for 
patients receiving LCZ696 and enalapril, respectively), sug-
gesting that the overall tolerability of LCZ696 at a dose of 200 
mg twice daily is not likely to be meaningfully different than 
the tolerability of enalapril 10 mg twice daily in clinical prac-
tice, even if the specific reasons for intolerance are different.
Some have suggested that the inclusion of a run-in period 
that allows for the withdrawal of drug-intolerant patients 
might lead to overestimation of size of the treatment bene-
fit during the randomized phase of the trial.5 To address the 
potential impact of patient selection during the run-in for the 
observed treatment benefit seen in PARADIGM-HF, we rean-
alyzed the study results by weighting participants according 
to the inverse probability of being included in the randomized 
Table 3. Multivariable Predictors of Dropout Before Randomization
Parameter
OR for Dropout  
(95% CI) Z Value
eGFR<60 1.49 (1.35–1.65) 7.72
NT-ProBNP (per log increment) 1.20 (1.14–1.26) 7.18
Randomization in Region 4 (Central/
Eastern Europe) vs. Elsewhere
0.68 (0.60–0.76) −6.64
Systolic BP  
(per 10 mm Hg decrease)
1.11 (1.07–1.14) 6.56
Ischemic cause of heart failure 1.25 (1.13–1.39) 4.20
BP indicates blood pressure; CI, confidence interval; eGFR, estimated 
glomerular filtration rate; NT-proBNP, N-terminal pro–B-type natriuretic peptide; 
OR, odds ratio.
Figure.  Impact of LCZ vs placebo on clinical outcomes in Pro-
spective Comparison of ARNI with an Angiotensin-Converting 
Enzyme Inhibitor to Determine Impact on Global Mortality and 
Morbidity in Heart Failure trial (PARADIGM-HF) with and without 
inverse probability weighting (IPW) for likelihood of randomization 
after run-in period.
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population. This approach has been applied in observational 
studies and in clinical trials in settings where not all patients 
are able to be observed over time,6,7 and attempts to reduce the 
effect of selection bias by assuming that run-in noncompletion 
is nonrandom, and more likely in particular types of patients; 
accordingly, patients most similar to those who dropped out 
during the run-in period are weighted more heavily in the final 
analysis. The method rests on the assumption that the key fac-
tors associated with noncompletion can be identified and that 
there are no significant unmeasured confounders. Although the 
weighted analysis cannot account for patient factors that are 
not in some measure represented in the randomized population 
(eg, factors that would have excluded patients from random-
ization), there was considerable overlap in the clinical pheno-
type of those who failed to complete the run-in and in those 
who were successfully randomized. In PARADIGM-HF, this 
inverse probability–weighted analysis produced nearly identi-
cal results to those seen in the primary analysis for all key 
outcome variables. Sensitivity analyses using overweighting 
to simulate extreme scenarios in which 50%, 80%, and 100% 
of the randomized population were similar to the patients who 
failed to complete the run-in period also did not alter the point 
estimates favoring LCZ696 over enalapril for all-cause mor-
tality or the primary composite outcome. Consistent results 
in an alternative analysis imputing neutral effect of random-
ized treatment to the run-in failure suggest that this result 
is not peculiar to the statistical methodology we used. Such 
model-based approaches to estimating the effects of therapy 
in alternative populations are inherently limited by the avail-
able baseline data and the extent to which run-in failure can 
be attributed to those characteristics used in the modeling pro-
cess. However, in aggregate, these data suggest that the size 
of the treatment effect of LCZ696 over enalapril during the 
randomized phase of the trial was not meaningfully influenced 
by the pattern of discontinuations during the run-in period.
Run-in periods have historically been a part of the 
design of many pivotal HF trials. The SOLVD-Treatment 
trial included a sequential run-in phase during which all 
screen-eligible patients were treated with enalapril 2.5 mg 
twice daily for 2 to 7 days followed by matching placebo 
for 14 to 17 days before randomization. Noncompletion of 
≈4.2% of patients (roughly half for adverse events and half 
for nonadherence) in each phase resulted in prerandomiza-
tion exclusion of 605 of 7402 (8.2%) initially eligible sub-
jects.8
 The Metoprolol CR/XL Randomized Intervention 
Trial in Heart Failure (MERIT-HF) included a 2-week, 
single-blind placebo run-in period designed primarily to 
assess patient adherence.9 As well, the US Carvedilol Heart 
Failure Study Group excluded 103 (8.6%) of 1197 other-
wise eligible patients during a 2-week run-in period dur-
ing which patients received carvedilol at a dose of 6.25 mg 
twice daily.10 Importantly, in nearly all of these cases, sub-
sequent analyses have affirmed the validity of the primary 
study results, suggesting that the study design did not intro-
duce important data distortions or confounding. Moreover, 
in practice, clinicians frequently use a run-in period during 
introduction of any new therapy, with initial challenge at 
low dose and subsequent titration, or discontinuation based 
on tolerability or patient preference.
We conclude that the effects of including a run-in period 
before randomization in PARADIGM-HF to ensure that 
patients tolerated both study drugs in the short term did not 
affect the magnitude of the treatment benefit of LCZ696 
over enalapril for any of the key outcomes of interest in 
PARADIGM-HF. Patients with low BP, eGFR <60 mL/min 
per 1.73 m2, and more advanced HF may have difficulty in 
tolerating target doses of both enalapril and LCZ696, and 
thus, should undergo closer monitoring during the uptitration 
of these drugs or the conversion of patients from enalapril 
to LCZ696 in clinical practice. The fact that many patients 
with these characteristics were successfully randomized in 
PARADIGM-HF despite the run-in period, however, high-
lights the difficulty in predicting study drug intolerance based 
on clinical criteria and underscores the importance of a thera-
peutic trial in selecting patients for treatment with LCZ696.
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CLINICAL PERSPECTIVE
Although run-in periods have been a part of the design of many pivotal heart failure clinical trials, some have questioned the 
implications of including a run-in period for the generalizability of study results as well as the anticipated magnitude of treat-
ment benefits for less-selected populations in clinical practice. The 8442 patients randomized in the Prospective Comparison 
of ARNI With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in 
Heart Failure (PARADIGM-HF) trial, in which sacubitril/valsartan (LCZ696) reduced both death and heart failure hospital-
ization more than enalapril, were a subset of 10 521 patients entering sequential, single-blind, run-in periods to ensure short-
term tolerability of the 2 study medications. In this analysis, we provide new data on the predictors of noncompletion during 
the run-in phase of PARADIGM-HF and estimate the implications of noncompletion for the overall study result. Among the 
20% of patients who did not complete the run-in period, roughly half discontinued the study drug during the 2-week enala-
pril run-in period and the balance during the 6-week LCZ696 run-in period. The majority of discontinuations was related to 
drug-related adverse events, and patients with lower blood pressure, higher natriuretic peptide levels, ischemic heart disease, 
and estimated glomerular filtration rate <60 mL/min per 1.73 m2 were higher risk for run-in noncompletion during either 
phase. Reanalysis of the randomized data assigning increased weight to patients with baseline characteristics most similar to 
those who failed to complete the run-in period did not influence the apparent benefit of LCZ696 over enalapril seen during 
the trial. Collectively, these data suggest that the inclusion of a run-in period did not meaningfully influence the observed 
study result for any of the key outcomes of interest in PARADIGM-HF.
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SUPPLEMENTAL MATERIAL  
 
Factors Associated with Noncompletion During the Run‐in Period Prior to Randomization and 
the Efficacy of LCZ696 in the PARADIGM‐HF Trial 
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Supplementary Methods 
 
Candidate Variables (measured at screening) included in stepwise multivariable modelling of 
run‐in noncompletion 
Age at screening (yrs) 
Region of Randomization (USA/Canada, Latin America, Western Europe and Other, Central/Eastern Europe, Asia‐
Pacific) 
Race or ethnic group (Caucasian, Black, Asian, Other) 
Sex (Male/Female) 
NYHA class at screening 
Diabetes (Y/N) 
B‐type natriuretic peptide level (pg/mL) 
‐ Continuous, log transformed  
‐ Categorical (above or ≤ median value) 
N‐terminal‐pro‐B‐type natriuretic peptide level (pg/mL) 
‐ Continuous, log transformed  
‐ Categorical (above or ≤ median value) 
Height (cm) 
Weight (kg) 
Body mass Index (kg/m2) 
Left Ventricular Ejection Fraction (%) 
‐ Continuous 
‐ Categorical (above or <=median value) 
Prior use of ACE‐inhibitor (Y/N) 
Prior use of Angiotensin Receptor Blocker (Y/N) 
Prior heart failure hospitalization (Y/N) 
Time since diagnosis of heart failure 
Prior history of hypertension (Y/N) 
Estimated Glomerular Filtration Rate (eGFR) mL/min/1.73m2 
‐ Continuous 
‐ Categorical (above or ≤ 60 mL/min/1.73 m2) 
Systolic blood pressure (mm Hg) 
‐ Continuous 
‐ Categorical (above or ≤ median value) 
Diastolic blood pressure (mm Hg), continuous 
Ischemic etiology for heart failure (Y/N) 
Prior history of unstable angina pectoris (Y/N) 
Prior history of myocardial infarction (Y/N) 
Prior history of percutaneous coronary intervention (Y/N) 
Prior history of coronary artery bypass grafting (Y/N) 
Prior history of atrial fibrillation (Y/N) 
Prior history of stroke (Y/N) 
Prior history of Implanted Cardioverter –Defibrillator (Y/N) 
Prior history of Cardiac Resynchronization Therapy (Y/N) 
Prior History of Coronary Heart Disease (Y/N) 
Prior history of Permanent Pacemaker Implantation (Y/N) 
Prior history of any angina pectoris (Y/N) 
 
 
Supplemental Table 1. Baseline Characteristics at Screening, According to Phase of Run‐In 
Noncompletion 
Characteristics at Screening 
Discontinued Study 
During Enalapril Run‐
In Phase  
(N=1102)
Discontinued 
Study During 
LCZ696 Run‐In 
Phase (N=977)  p
Age (yrs)  65.12 ± 11.41 64.33 ± 12.16  0.13
Region    0.36
  USA/Canada 123 (11.2%) 95 (9.7%)  
Latin America 205 (18.6%) 176 (18.0%)  
Western Europe and Other 294 (26.7%) 299 (30.6%)  
Central/Eastern Europe 276 (25.0%) 236 (24.2%)  
Asia‐Pacific 204 (18.5%) 171 (17.5%)  
Race or Ethnic Group    0.81
Caucasian 689 (62.5%) 625 (64.0%)  
Black 66 (6.0%) 65 (6.7%)  
Asian 206 (18.7%) 174 (17.8%)  
Other 141 (12.8%) 113 (11.6%) 
Female Sex  274 (24.9%) 225 (23.0%)  0.33
Height (cm)  167.33 ± 10.18 168.07 ± 9.97  0.09
Weight (kg)  77.19 ± 18.75 78.60 ± 20.00  0.1
Systolic BP (mm Hg)  125.30 ± 17.31 124.53 ± 16.72  0.3
BMI (kg/m2)   27.39 ± 5.54 27.62 ± 5.83  0.35
eGFR (mL/min/1.73m2)  63.2 ± 22.9 64.8 ± 22.2  0.09
Serum creatinine (mg/dL)  1.22 ± 0.37 1.18 ± 0.33  0.04
NYHA Class    0.27
I/II 663 (60.2%) 611 (62.5%) 
III/IV 435 (39.6%) 363 (37.3%) 
Median NT‐proBNP (pg/mL) [IQR]  2057 [985, 4838] 2078 [1033, 4510]  0.87
Ejection Fraction (%)  28.4 ± 6.5 28.6 ± 6.6  0.43
Ischemic Etiology  721 (65.4%) 604  (61.8%)  0.09
ICD  213 (19.3%) 204 (20.9%)  0.38
CRT  105 (9.5%) 94 (9.6%)  0.94
Diabetes  403 (36.6%) 350 (35.8%)  0.72
Hypertension  748 (67.9%) 623 (63.8%)  0.048
Coronary Heart Disease  612 (55.5%) 537 (55.0%)  0.79
Atrial Fibrillation  373 (33.8%) 324 (33.2%)  0.74
Pretrial Use of ACE‐I  811 (73.7%) 767 (78.5%)  0.01
Pretrial Use of ARB  286 (26.0%) 213 (21.8%)  0.026
 
Supplemental Table 2. Predictors of noncompletion during the run‐in period by phase 
  Noncompletion during Enalapril 
Run‐in 
Noncompletion during LCZ696 
Run‐in* 
Parameter  OR for Dropout (95% 
CI) 
Z  OR for Dropout (95% 
CI) 
Z 
eGFR < 60  1.54 (1.36‐1.76)  6.54  1.35 (1.18, 1.55)  4.24 
NT‐ProBNP  
(per log increment) 
1.17 (1.09‐1.24)  4.70  1.23 (1.15‐1.32)  5.86 
Randomization in  
Region 4 
(Central/Eastern 
Europe) vs. Elsewhere 
0.71 (0.61‐0.82)  ‐4.55  0.69 (0.59‐0.81)  ‐4.63 
Systolic Blood Pressure 
(per 10 mm Hg 
decrease) 
1.08 (1.04‐1.12)  3.86     
Diastolic Blood 
Pressure (per 10 mm 
Hg decrease) 
    1.19 (1.11‐1.27)  5.16 
Ischemic Etiology   1.30 (1.14‐1.49)  3.81     
*Only patients successfully completing enalapril run‐in were eligible for LCZ696 run‐in 
 
 
 
 
Supplemental Table 3. Sensitivity analyses estimating the effect of LCZ696 relative to 
enalapril on mortality and the primary composite in PARADIGM‐HF in inverse probability 
weighted models reflecting hypothetical populations with different proportions of 
noncompletion during the run‐in period.  
 
    Treatment HR (LCZ696 vs. Enalapril)
Patient Mix  Population  Mean
eGFR 
Mean
SBP 
Median
NT‐proBNP 
Mortality Rate
(per 100 pt‐yrs)  Death  Primary Composite 
Unadjusted 
100% randomized 
8399 randomized  68  128  1615  8.3  0.84 (0.76‐0.93)  0.80 (0.73‐0.87) 
Screened Population: 
20% run‐in failures 
80% randomized 
 
2079 run‐in failures 
8442 randomized 
67  128  1693  8.7  0.84 (0.76‐0.92)  0.80 (0.73‐0.87) 
50% run‐in failures 
50% randomized 
5260 run‐in failures 
5260 randomized  66  127  1806  9.2  0.83 (0.75‐0.92)  0.80 (0.73‐0.88) 
80% run‐in failures 
20% randomized 
8442 run‐in failures 
2079 randomized  65  126  1934  9.6  0.82 (0.74‐0.92)  0.80 (0.73‐0.88) 
100% run‐in failures  10521 run‐in failures  64 125 2007 9.9 0.82 (0.73‐0.92) 0.80 (0.73‐0.89)
 
 
 
Supplemental Table 4. Sensitivity Analysis of Effects of LCZ696 vs. Enalapril on PARADIGM‐HF 
Primary Composite Endpoint Imputing Neutral Effect of Randomized Treatment for Run‐in 
Failures Across a Range of Assumed Event Rates 
Assumed Event Rate 
for Run‐in Failures (per 
100 py) 
Event Rate Relative 
to Observed
Average HR  
(LCZ696 vs. Enalapril) Average CI 
11.8  Observed 0.84 (0.78, 0.91) 
23.6  100% increase 0.86 (0.80, 0.92) 
35.4  200% increase 0.86 (0.81, 0.93) 
 
